Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

  • Technology appraisal guidance
  • TA389
  • Published: 

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222): notice of appeal

The Institute has received one appeal from PharmaMar.

The Appeal hearing planned to take place on Thursday 26 March 2015 will be reconvened.

The Institute awaits the decision of the Appeal panel.

This page was last updated: 26 March 2015